Literature DB >> 1452658

Susceptibility testing of Cryptococcus neoformans: a microdilution technique.

M A Ghannoum1, A S Ibrahim, Y Fu, M C Shafiq, J E Edwards, R S Criddle.   

Abstract

We studied a series of test conditions in a microtiter system to define the optimal method for determining the susceptibility of Cryptococcus neoformans to antifungal agents. Twenty-one isolates of C. neoformans were grown for 24 or 48 h in four chemically defined media: yeast nitrogen base (BYNB 7); RPMI 1640; synthetic amino acid medium--fungal (SAAMF), buffered at pH 7.0 to select the medium that best supported growth of this fastidious yeast; and yeast nitrogen base, pH 5.4 (YNB 5.4). Maximum growth of C. neoformans, at 35 degrees C, was obtained in YNB 5.4, with the next highest growth levels in BYNB 7, SAAMF, and RPMI. Growth at 24 h was uniformly poor in all media and lacked reproducibility. In contrast, incubation for 48 h gave adequate growth with low standard deviations, and 48 h was selected as the optimal incubation period for this study. Comparison of the relationship between growth kinetics and initial inoculum size for eight cryptococcal isolates showed that 10(4) cells per ml yielded optimal growth in BYNB 7 and YNB 5.4, whereas 10(5) cells per ml was optimal in RPMI and SAAMF. Furthermore, variation of inocula from 10(3) to 10(5) cells per ml showed small but significant inoculum effects in determining MICs of fluconazole, amphotericin B, and flucytosine for C. neoformans. Therefore, 10(4) cells per ml was chosen as the optimal inoculum for susceptibility testing in this study. Mean MICs of fluconazole, amphotericin B, and flucytosine for 21 crytococcal isolates in RPMI and BYNB 7 were low (for example, fluconazole had mean MICs of 1.2 and 1.3 micrograms/ml in RPMI and BYNB 7, respectively) and differed significantly from medium to medium. In contrast, the MICs obtained in SAAMF were significantly higher (e.g., fluconazole had a mean MIC of 2.2 micrograms/ml). Variance in MICs was large with fluconazole and flucytosine but small with amphotericin B, irrespective of the medium used. A microtiter system employing BYNB 7 as the medium, 48 h as the incubation period, and 10(4) cells per ml as the final inoculum is a simple, accurate, and reproducible method for the testing of C. neoformans susceptibility to fluconazole, amphotericin B, and flucytosine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1452658      PMCID: PMC270546          DOI: 10.1128/jcm.30.11.2881-2886.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  18 in total

1.  Effects of antineoplastic agents on growth, morphology and metabolism of Torulopsis glabrata.

Authors:  M A Ghannoum
Journal:  Mycopathologia       Date:  1986-09       Impact factor: 2.574

2.  Maintenance amphotericin B for cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS).

Authors:  A Zuger; M Schuster; M S Simberkoff; J J Rahal; R S Holzman
Journal:  Ann Intern Med       Date:  1988-10-01       Impact factor: 25.391

3.  Cryptococcal infections in patients with acquired immune deficiency syndrome.

Authors:  R H Eng; E Bishburg; S M Smith; R Kapila
Journal:  Am J Med       Date:  1986-07       Impact factor: 4.965

4.  Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods.

Authors:  J N Galgiant; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

5.  Collaborative investigation of variables in susceptibility testing of yeasts.

Authors:  M A Pfaller; M G Rinaldi; J N Galgiani; M S Bartlett; B A Body; A Espinel-Ingroff; R A Fromtling; G S Hall; C E Hughes; F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

6.  Quantitative microculture system with standardized inocula for strain typing, susceptibility testing, and other physiologic measurements with Candida albicans and other yeasts.

Authors:  F C Odds
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

7.  Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment.

Authors:  A Zuger; E Louie; R S Holzman; M S Simberkoff; J J Rahal
Journal:  Ann Intern Med       Date:  1986-02       Impact factor: 25.391

8.  Assay for yeast susceptibility to 5-fluorocytosine and amphotericin B in a frozen microtiter system.

Authors:  N S Ellis; M S Bartlett; J W Smith
Journal:  Am J Clin Pathol       Date:  1979-08       Impact factor: 2.493

9.  Comparison study of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; T M Kerkering; P R Goldson; S Shadomy
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

10.  Comparison of microdilution and broth dilution techniques for the susceptibility testing of yeasts to 5-fluorocytosine and amphotericin B.

Authors:  M F Mazens; G P Andrews; R C Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

View more
  47 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Fluorometric assessment of In vitro antidermatophytic activities of antimycotics based on their keratin-penetrating power.

Authors:  C N Okeke; R Tsuboi; M Kawai; H Ogawa
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Clinical case of endocarditis due to Trichosporon inkin and antifungal susceptibility profile of the organism.

Authors:  Jose M Ramos; Manuel Cuenca-Estrella; Felix Gutierrez; Matilde Elia; Juan L Rodriguez-Tudela
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

4.  In vitro antifungal activities of inhibitors of phospholipases from the fungal pathogen Cryptococcus neoformans.

Authors:  Ranjini Ganendren; Fred Widmer; Vatsala Singhal; Christabel Wilson; Tania Sorrell; Lesley Wright
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

5.  Influence of shaking on antifungal susceptibility testing of Cryptococcus neoformans: a comparison of the NCCLS standard M27A medium, buffered yeast nitrogen base, and RPMI-2% glucose.

Authors:  J L Rodríguez-Tudela; F Martín-Díez; M Cuenca-Estrella; L Rodero; Y Carpintero; B Gorgojo
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

6.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.

Authors:  M E Brandt; M A Pfaller; R A Hajjeh; R J Hamill; P G Pappas; A L Reingold; D Rimland; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

7.  Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose.

Authors:  A Espinel-Ingroff; M Pfaller; M E Erwin; R N Jones
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

8.  Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test.

Authors:  J van Eldere; L Joosten; V Verhaeghe; I Surmont
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

9.  Genotyping and antifungal susceptibility profile of Dipodascus capitatus isolates causing disseminated infection in seven hematological patients of a tertiary hospital.

Authors:  Ignacio Gadea; Manuel Cuenca-Estrella; Elena Prieto; Teresa M Diaz-Guerra; Jose I Garcia-Cia; Emilia Mellado; Jose F Tomas; Juan L Rodriguez-Tudela
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

10.  Fungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitro.

Authors:  M S Alcouloumre; M A Ghannoum; A S Ibrahim; M E Selsted; J E Edwards
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.